Skip to content
Faron, etusivu
Releases and publications
Careers
Contact Information
Search for:
LANGUAGE
English
Suomi
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Forecasts and analysis, Analysts
Outlook
Share and shareholders
Share information
Shareholders
Share monitor
Management ownership and transactions
Warrants
Public offering 2024
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
For Patients
About
Management
Board of directors
Scientific Advisory Board
Sustainability
Pipeline
Our science
Clinical trials
Drug candidates
Investors
Faron as an investment
Strategy
Faron’s business
Market overview
Key financials
Forecasts and analysis, Analysts
Outlook
Share and shareholders
Share information
Shareholders
Share monitor
Management ownership and transactions
Warrants
Public offering 2024
AIM rule 26
Governance
Advisors
Articles of association
Auditor
Board committees
General Meeting
Insider management
Remuneration
Risk management and internal control
Reports and presentations
Investor relations
Disclosure policy
Investor calendar
Contact Information
For Patients
Releases and publications
Careers
Contact Information
Search for:
LANGUAGE
English
Suomi
Public offering 2024
Please select the public offering you want to learn more about:
Finnish Public Offering and EEA Institutional Offering
UK Open Offer to DI Holders
Back to top
